Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Hypoparathyroidism

Endocrine & Hormonal

Hypoparathyroidism Clinical Trials and Treatments

Also called Parathyroid Insufficiency, Hypocalcemia with Hyperphosphatemia, Chronic Hypoparathyroidism

Hypoparathyroidism disrupts the body's calcium regulation system. Normally, the four parathyroid glands (tiny structures behind the thyroid) secrete PTH in response to falling blood calcium.

In plain words, hypoparathyroidism happens when the body makes too little of a hormone that keeps calcium in the blood at the right level. Most often the small glands that make it are hurt or removed during neck surgery, leading to tingling and muscle cramps.

Get an email when new Hypoparathyroidism trials open or the FDA decides. Get alerts

Hypoparathyroidism

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 18 studies with no phase, like observational studies, and 1 phase 4 study following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines3

Yorvipath · Drisdol · Rocaltrol

Hypoparathyroidism has 3 FDA-approved medicines, 25 open or active clinical trials (22 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Hypoparathyroidism

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Hypoparathyroidism

PTH then raises calcium by pulling it from bones, increasing kidney reabsorption, and activating vitamin D to boost intestinal calcium absorption. When PTH is absent or insufficient, blood calcium drops and phosphorus rises, creating a state of neuromuscular irritability that can range from mild tingling to life-threatening seizures and cardiac arrhythmias.

Keep reading about Hypoparathyroidism

For decades, treatment was limited to high-dose calcium and active vitamin D supplements, which manage symptoms but don't restore normal physiology and carry risks of kidney damage from excess calcium in the urine. In August 2024, the FDA approved Yorvipath (palopegteriparatide), developed by Ascendis Pharma, for hypoparathyroidism in adults. It is now the only PTH replacement therapy sold in the US.

Yorvipath is a once-daily subcutaneous injection that releases a PTH analog to restore more normal calcium regulation. An earlier PTH replacement, Natpara (rhPTH[1-84]), was recalled in 2019 due to rubber particulate contamination and was ultimately discontinued by Takeda at the end of 2024.

What are the symptoms of Hypoparathyroidism?

These are common symptoms of Hypoparathyroidism, and how strong they are varies from person to person.

  • Tingling and numbness around the mouth, hands, and feet (paresthesias)
  • Muscle cramps and spasms, particularly in the hands and feet (carpopedal spasms)
  • Tetany with uncontrollable muscle twitching and cramping
  • Seizures in more severe or untreated cases
  • Laryngospasm (spasm of the voice box) causing breathing difficulty
  • Cardiac arrhythmias from prolonged low calcium levels
  • Chronic fatigue and generalized weakness
  • Anxiety, depression, and difficulty concentrating (brain fog)
  • Brittle nails, dry skin, and coarse hair
  • Kidney stones and calcium deposits in soft tissues over time

Who gets Hypoparathyroidism?

Hypoparathyroidism can occur at any age. The majority of cases result from surgical complications during thyroidectomy, parathyroidectomy, or other neck procedures. The remaining cases are genetic (including DiGeorge syndrome from 22q11.2 deletion), autoimmune, or idiopathic.

It affects males and females, though postsurgical cases are more common in women. Genetic forms can follow autosomal dominant or autosomal recessive inheritance patterns.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Hypoparathyroidism?

There are currently 3 FDA-approved medications for Hypoparathyroidism.

palopegteriparatide
Ascendis Pharma
Search
Drisdol
ergocalciferol (50,000iu rx)
Rocaltrol
calcitriol (oral)

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Hypoparathyroidism treatment

Charity funds and drugmaker programs for Hypoparathyroidism, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · The Assistance Fund
    Hypoparathyroidism fund
    Open

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 20, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Hypoparathyroidism, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Hypoparathyroidism

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Hypoparathyroidism resources

Reputable organizations and medical references for learning more about Hypoparathyroidism, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Hypoparathyroidism

Use this Hypoparathyroidism clinical trial finder to see the 22 studies recruiting patients and 3 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 13 test a treatment and 12 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

25 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT07699471

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

Intervention: Canvuparatide, Placebo

Sponsor: MBX Biosciences

The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).

Ages 18 Years+
Started Aug 2026Updated 4 days agoEst. Jan 2028 (~1y 2m)
RecruitingTreatment trialRecently updatedNCT07617584

NIRAF-Guided Parathyroid Identification During Thyroidectomy

Intervention: Wearable Near-Infrared Autofluorescence Imaging System

Sponsor: Ss. Cyril and Methodius University of Skopje

This study evaluates whether a wearable near-infrared autofluorescence (NIRAF) imaging system can help surgeons identify and preserve parathyroid glands during thyroid surgery. These small glands produce parathyroid hormone (PTH), which helps control blood calcium. The modified M...

Ages 18 Years+1 location
Started Sep 2026Updated 4 days agoEst. Jun 2029 (~2y 6m)
RecruitingTreatment trialPhase 3Recently updatedNCT07805356

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

Intervention: Encaleret, Placebo

Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company

The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).

Ages 16 Years+
Started Aug 2026Updated 1 week agoEst. Jan 2028 (~1y 2m)
RecruitingTreatment trialPhase 3Recently updatedNCT07081997

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Intervention: Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm

Sponsor: Ascendis Pharma Bone Diseases A/S

This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and p...

Ages 18 Years+
Started May 2026Updated 2 weeks agoEst. Jun 2027 (~7 months)
RecruitingObservational study, no treatment givenRecently updatedNCT07857460

German Hypoparathyroidism Registry

Sponsor: University Hospital Augsburg · Ascendis Pharma Endocrinology Division A/S

Chronic hypoparathyroidism is a rare condition in which the parathyroid glands do not make enough parathyroid hormone (PTH). PTH helps control the levels of calcium and phosphate in the blood. When there is not enough PTH, calcium levels can become too low and phosphate levels ca...

Ages 18 Years+1 location
Started Jul 2021Updated 1 month agoEst. Feb 2036 (~9y 2m)
Find Hypoparathyroidism trials near you, ranked by distance →
Active trial locations38 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+30 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Hypoparathyroidism trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Hypoparathyroidism foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Hypoparathyroidism patient communities

Facebook groups, Reddit communities and YouTube channels where Hypoparathyroidism patients, caregivers and advocacy groups talk.

Companies developing Hypoparathyroidism treatments

Drugmakers that list Hypoparathyroidism in their rare disease portfolio, 4 in all.

Questions people ask about Hypoparathyroidism